Cargando…

Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments

Non-alcoholic steatohepatitis (NASH) develops from non-alcoholic fatty liver disease (NAFLD). Currently, around 25% of the population is estimated to have NAFLD, and 25% of NAFLD patients are estimated to have NASH. NASH is typically characterized by liver steatosis inflammation, and fibrosis driven...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peng, Cheng, Stewart, Alastair G., Woodman, Owen L., Ritchie, Rebecca H., Qin, Cheng Xue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745178/ https://www.ncbi.nlm.nih.gov/pubmed/33343375 http://dx.doi.org/10.3389/fphar.2020.603926

Ejemplares similares

Fructose and Non-Alcoholic Steatohepatitis
por: Roeb, Elke, et al.
Publicado: (2021)

Current, emerging, and potential therapies for non-alcoholic steatohepatitis
por: Yang, Zhen, et al.
Publicado: (2023)

Chymase Inhibitor as a Novel Therapeutic Agent for Non-alcoholic Steatohepatitis
por: Takai, Shinji, et al.
Publicado: (2018)

The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment
por: Yu, Lili, et al.
Publicado: (2022)

Exploring the molecular mechanism of Gan Shuang granules for the treatment of non-alcoholic steatohepatitis using network pharmacology, molecular docking, and experimental verification
por: Zhi, Guoguo, et al.
Publicado: (2023)

The Target MicroRNAs and Potential Underlying Mechanisms of Yiqi-Bushen-Tiaozhi Recipe against‐Non-Alcoholic Steatohepatitis
por: Hong, Wei, et al.
Publicado: (2020)

A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis
por: Kawaguchi-Suzuki, Marina, et al.
Publicado: (2018)

Artemether Ameliorates Non-Alcoholic Steatohepatitis by Repressing Lipogenesis, Inflammation, and Fibrosis in Mice
por: Xu, Jia, et al.
Publicado: (2022)

Therapeutic effect of fenofibrate for non-alcoholic steatohepatitis in mouse models is dependent on regime design
por: Wang, Xinxue, et al.
Publicado: (2023)

Editorial: Inflammation in Cardiovascular Diseases: Role of the Endothelium and Emerging Therapeutics
por: Qin, Cheng Xue, et al.
Publicado: (2020)

Extracts of Vine Tea Improve Diet-Induced Non-Alcoholic Steatohepatitis Through AMPK-LXRα Signaling
por: Chen, Yu-jun, et al.
Publicado: (2021)

Licorice extract inhibits the cGAS-STING pathway and protects against non-alcoholic steatohepatitis
por: Luo, Wei, et al.
Publicado: (2023)

Diabetes Attenuates the Contribution of Endogenous Nitric Oxide but Not Nitroxyl to Endothelium Dependent Relaxation of Rat Carotid Arteries
por: Li, Jasmin Chendi, et al.
Publicado: (2021)

Geniposide and Chlorogenic Acid Combination Ameliorates Non-alcoholic Steatohepatitis Involving the Protection on the Gut Barrier Function in Mouse Induced by High-Fat Diet
por: Peng, Jing-hua, et al.
Publicado: (2018)

Bicyclol attenuates high fat diet-induced non-alcoholic fatty liver disease/non-alcoholic steatohepatitis through modulating multiple pathways in mice
por: Wu, Jingyi, et al.
Publicado: (2023)

Cyclophilin Inhibitor NV556 Reduces Fibrosis and Hepatocellular Carcinoma Development in Mice With Non-Alcoholic Steatohepatitis
por: Kuo, Joseph, et al.
Publicado: (2019)

Berberine Alleviates Non-alcoholic Steatohepatitis Through Modulating Gut Microbiota Mediated Intestinal FXR Activation
por: Shu, Xiangbing, et al.
Publicado: (2021)

Rifaximin Ameliorates Non-alcoholic Steatohepatitis in Mice Through Regulating gut Microbiome-Related Bile Acids
por: Jian, Jie, et al.
Publicado: (2022)

Research landscape and frontiers of non-alcoholic steatohepatitis-associated hepatocellular carcinoma: a bibliometric and visual analysis
por: Gao, Bowen, et al.
Publicado: (2023)

Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
por: Lee, Kuei-Chuan, et al.
Publicado: (2023)

Erratum: Bicyclol attenuates high fat diet-induced non-alcoholic fatty liver disease/non-alcoholic steatohepatitis through modulating multiple pathways in mice
por: Frontiers Production Office,
Publicado: (2023)

Evaluation of the efficacy of mitochondrial fission inhibitor (Mdivi-1) using non-alcoholic steatohepatitis (NASH) liver organoids
por: Elbadawy, Mohamed, et al.
Publicado: (2023)

Geniposide plus chlorogenic acid reverses non-alcoholic steatohepatitis via regulation of gut microbiota and bile acid signaling in a mouse model in vivo
por: Li, Hongshan, et al.
Publicado: (2023)

Medicinal Formula Huazhi-Rougan Attenuates Non-Alcoholic Steatohepatitis Through Enhancing Fecal Bile Acid Excretion in Mice
por: Li, Chunlin, et al.
Publicado: (2022)

Obeticholic acid and ferrostatin-1 differentially ameliorate non-alcoholic steatohepatitis in AMLN diet-fed ob/ob mice
por: Li, Shengjie, et al.
Publicado: (2022)

Nitroxyl: A Novel Strategy to Circumvent Diabetes Associated Impairments in Nitric Oxide Signaling
por: Velagic, Anida, et al.
Publicado: (2020)

Immunological Mechanisms in the Pathophysiology of Non-Alcoholic Steatohepatitis
por: Vonghia, Luisa, et al.
Publicado: (2013)

Mechanisms of ductular reaction in non-alcoholic steatohepatitis
por: Chen, Yue, et al.
Publicado: (2022)

Gut-Derived Serotonin Contributes to the Progression of Non-Alcoholic Steatohepatitis via the Liver HTR2A/PPARγ2 Pathway
por: Wang, Lulu, et al.
Publicado: (2020)

Herbal Medicine in the Treatment of Non-Alcoholic Fatty Liver Diseases-Efficacy, Action Mechanism, and Clinical Application
por: Xu, Yu, et al.
Publicado: (2020)

Molecular Mechanisms and New Treatment Strategies for Non-Alcoholic Steatohepatitis (NASH)
por: Takaki, Akinobu, et al.
Publicado: (2014)

Combined alcoholic and non-alcoholic steatohepatitis
por: Ntandja Wandji, Line Carolle, et al.
Publicado: (2020)

Anti-Autophagy Mechanism of Zhi Gan Prescription Based on Network Pharmacology in Nonalcoholic Steatohepatitis Rats
por: Qin, Chufeng, et al.
Publicado: (2021)

Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment
por: Zhu, Bo, et al.
Publicado: (2021)

Novel Molecular Mechanisms in the Development of Non-Alcoholic Steatohepatitis
por: Povero, Davide, et al.
Publicado: (2016)

Kaempferol Alleviates Steatosis and Inflammation During Early Non-Alcoholic Steatohepatitis Associated With Liver X Receptor α-Lysophosphatidylcholine Acyltransferase 3 Signaling Pathway
por: Xiang, Hongjiao, et al.
Publicado: (2021)

Si-Wei-Qing-Gan-Tang Improves Non-Alcoholic Steatohepatitis by Modulating the Nuclear Factor-κB Signal Pathway and Autophagy in Methionine and Choline Deficient Diet-Fed Rats
por: Xiao, Lingyun, et al.
Publicado: (2020)

Statins in Non-alcoholic Steatohepatitis
por: Torres-Peña, Jose D., et al.
Publicado: (2021)

Transcriptomics data of a human in vitro model of non-alcoholic steatohepatitis exposed to elafibranor
por: Boeckmans, Joost, et al.
Publicado: (2019)

Role of Alcohol Metabolism in Non-Alcoholic Steatohepatitis
por: Baker, Susan S., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_hubihi39e0j8o468a528e8i6t5